Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00508950 · ClinicalTrials.gov registry record · NA

Study Evaluating Serum Collected From Healthy Adults For Development of Pneumococcal Opsonophagocytic Assay

A NA study of Healthy, sponsored by Pfizer.

Completed
Registry status
NA
Development phase
152
Enrollment target
1
Study location

NCT00508950: Completed NA study of Healthy, sponsored by Pfizer.

NCT00508950 is a NA study of Healthy that has completed, run by Pfizer. The registered enrollment target is 152 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00508950, a NA study of Healthy, has completed, sponsored by Pfizer.

COMPLETED
Registry status
NA
Development phase
152 participants
Enrollment target
1
Study location

Study Summary

The study will identify healthy adults who have been vaccinated against pneumococcus, and collect blood for the purpose of developing laboratory assays.

Conditions Studied

Interventions

  • PROCEDURE Large volume blood draw

Study Locations (1)

New Jersey

  • Frontage Clinical Services Inc. - Secaucus

Trial Details

FieldValue
Enrollment Target 152 participants
Start Date 2007-08
Est. Completion 2016-06
Phase NA
Pfizer

1,845 total trials

What the finished NCT00508950 record still lists

NCT00508950 is an interventional study that assigns participants to a tested intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (77% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which Large volume blood draw is the first listed.

NCT00508950 reports a single indexed study location in New Jersey.

Frequently Asked Questions

What is clinical trial NCT00508950 about?

NCT00508950 is a clinical study titled "Study Evaluating Serum Collected From Healthy Adults For Development of Pneumococcal Opsonophagocytic Assay". The study will identify healthy adults who have been vaccinated against pneumococcus, and collect blood for the purpose of developing laboratory assays.

What is the current status of trial NCT00508950?

This trial is currently completed. It is a NA study. The enrollment target is 152 participants. The study started on 2007-08. Estimated completion is 2016-06.

What conditions does trial NCT00508950 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT00508950?

The interventions under investigation include: Large volume blood draw (PROCEDURE).

Who is sponsoring clinical trial NCT00508950?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00508950 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00508950's enrollment target sits among peer trials

152 150th of 1090 higher than 941 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03328078 · 152 participants · Phase 1

    CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

  • NCT04458532 · 152 participants · NA

    Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer

  • NCT04858334 · 152 participants · Phase 2

    APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

  • NCT04993859 · 152 participants

    Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00508950, the US trial registry maintained by the National Library of Medicine. NCT00508950 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.